# Lumexa Imaging (LMRI) — Analyst Forecast

LMRI · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lmri/forecast

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 5, 2026 | Truist Securities | Initiated Coverage | Buy | $18.00 |
| Sep 25, 2026 | Keybanc | Initiated Coverage | Overweight | $18.00 |
| Aug 28, 2026 | Barclays | Maintained | Overweight | $13.00 |
| May 20, 2026 | Barclays | Maintained | Overweight | $9.00 |
| Apr 14, 2026 | Barclays | Maintained | Overweight | $15.00 |
| Feb 9, 2026 | Raymond James | Upgraded | Outperform → Strong Buy | $23.00 |
| Jan 5, 2026 | William Blair | Initiated Coverage | Outperform | — |
| Jan 5, 2026 | Jefferies | Initiated Coverage | Buy | $23.00 |
| Jan 5, 2026 | Wells Fargo | Initiated Coverage | Overweight | $22.00 |
| Jan 5, 2026 | Barclays | Initiated Coverage | Overweight | $23.00 |
| Jan 5, 2026 | Raymond James | Initiated Coverage | Outperform | $23.00 |
| Jan 5, 2026 | Leerink Partners | Initiated Coverage | Outperform | $23.00 |
| Jan 5, 2026 | Deutsche Bank | Initiated Coverage | Buy | $22.00 |

## Frequently Asked Questions

### What is the latest analyst rating on LMRI?

On Oct 5, 2026, Truist Securities initiated coverage of Lumexa Imaging at Buy with a price target of $18.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).